Biomedicine is a priority sector for Taiwan. The government has goals to establish Taiwan as the capital of biomedical research and development in the Asia-Pacific region. The country is striving to develop 20 new medicines, bring 80 high-value medical devices to market, and build biomedicine into a trillion-NT-dollar industry by 2025. Tax incentives and other credits will help expand the scale of the biotech and pharmaceutical industry.

Service Carveouts; Disease Managemen; Oncology. Vida Healthcare is positioning itselaf as a "value manager" serving patients, physicians and payers as it seeks to develop local best practices in oncology for physicians, intervene with patients and ultimately develop a body of clinical and outcomes information.

Physicians are joining together under unified management structures to become more efficient, able competitors in an increasingly capitated world. Efforts are farthest along in the lucrative and growing market for cancer treatment, but specialty physician groups of all kinds are moving to stake turf and sell their services to managed care. Information technology will be key to balancing quality and cost--and proving it.